◎ Sugi Atlas

Atlas / Disease / Female breast carcinoma

Female breast carcinoma

disease
On this page

Also known as breast carcinoma, femalecarcinoma of female breastcarcinoma of the female breastfemale breast cancermammary carcinoma of female breastmammary carcinoma of the female breast

Summary

Female breast carcinoma (MONDO:0004379) is a cancer (an umbrella term covering 7 Mondo subtypes) and 35 clinical trials. Top therapeutic interventions include goserelin, anastrozole, and atracurium besylate. A subtype of breast carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Classification: Cancer
  • Umbrella term: 7 Mondo subtypes
  • Clinical trials: 35

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namefemale breast carcinoma
Mondo IDMONDO:0004379
DOIDDOID:0050671, DOID:7843
NCITC2918
SNOMED CT372064008, 447782002
UMLSC0007104
MedGen40099
Is cancer (heuristic)yes

Also known as: breast carcinoma, female · carcinoma of female breast · carcinoma of the female breast · female breast cancer · female breast carcinoma · mammary carcinoma of female breast · mammary carcinoma of the female breast

Data availability: 20 cell lines.

Disease family

This is a subtype of breast carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › breast carcinoma › female breast carcinoma

Related subtypes (12): nipple carcinoma, bilateral breast carcinoma, sporadic breast cancer, breast carcinoma in situ, breast adenocarcinoma, male breast carcinoma, breast carcinoma by gene expression profile, invasive breast carcinoma, Ehrlich tumor carcinoma, hereditary breast carcinoma, cribriform carcinoma of breast, hormone-resistant breast carcinoma

Subtypes (7): female breast nipple and areola cancer, female breast central part cancer, female breast lower-outer quadrant cancer, female breast upper-inner quadrant cancer, female breast lower-inner quadrant cancer, female breast axillary tail cancer, female breast upper-outer quadrant cancer

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 35.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified23
PHASE25
PHASE33
PHASE42
PHASE11
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02005770PHASE4COMPLETEDAnesthesia and Circulating Tumor Cells in Breast Cancer
NCT02089854PHASE4UNKNOWNAdjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer
NCT06144164PHASE3RECRUITINGA Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
NCT05438810PHASE3UNKNOWNThis is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
NCT05439499PHASE3UNKNOWNThis is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
NCT02942355PHASE2ACTIVE_NOT_RECRUITINGTrial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer
NCT06092892PHASE2RECRUITINGIIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases
NCT01083641PHASE2TERMINATEDEstrogen for Triple Negative Breast Cancer
NCT01671319PHASE2COMPLETEDDose Dense TC + Pegfilgrastim Support for Breast Cancer
NCT02540330PHASE2TERMINATEDA Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant
NCT05755581PHASE1UNKNOWNEfficacy of Neoadjuvant Endocrine Therapy Compared to Chemotherapy in Breast Cancer Patients
NCT06145399EARLY_PHASE1WITHDRAWNA Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer
NCT01230346Not specifiedACTIVE_NOT_RECRUITINGCulturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer
NCT05586256Not specifiedRECRUITINGUltra-hypofractionated Radiotherapy in Breast Cancer Patients
NCT05792150Not specifiedRECRUITINGPROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS
NCT06618690Not specifiedACTIVE_NOT_RECRUITINGExercise Program on Pain, Physical Function, and Quality of Life in Breast Cancer Survivors
NCT06696378Not specifiedRECRUITINGMelatonin Supplementation and Exercise Program in Breast Cancer Women
NCT07436078Not specifiedRECRUITINGCulturally Adapting an Intervention to Increase Genetic Testing in African American Cancer Survivors
NCT01320488Not specifiedSUSPENDEDBreast Cancer in Young Women: Is it Different?
NCT01643148Not specifiedCOMPLETEDThe Tetrad BMI, Leptin, Leptin/Adiponectin (L/A) Ratio and CA-15-3 is a Reliable Biomarker of Breast Cancer
NCT01741883Not specifiedUNKNOWNSide Effect Prevention Training (SEPT) for Nocebo Effects in Breast Cancer Patients
NCT02088710Not specifiedUNKNOWNExpectations and Side Effects of Endocrine Therapy in Women With Breast Cancer
NCT02243163Not specifiedUNKNOWNEffect of Yoga on Life Quality and Immunity in Breast Cancer Patients After Operation and or Chemotherapy
NCT02480933Not specifiedUNKNOWNSilent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens
NCT03005860Not specifiedWITHDRAWNEffect of TIVA Propofol vs Sevoflurane Anaesthetic on Serum Biomarkers and on PBMCs in Breast Cancer Surgery
NCT03059875Not specifiedUNKNOWNPlace of Comprehensive Geriatric Assessment in Patients ≥ 75 Years Care, With Breast Cancer, After Screening With FOG (Oncology Geriatric Filter)
NCT03153631Not specifiedUNKNOWNFemale Sexual Dysfunction in Breast Cancer Patients
NCT03836872Not specifiedTERMINATEDAcupuncture for Joint Symptoms in Patients With Breast Cancer
NCT04290585Not specifiedCOMPLETEDTechnology and Health Communication in Improving Health Outcomes in Patients Scheduled for Mammography
NCT04775290Not specifiedUNKNOWNYoga on QOL Physiological Distress&Fatigue, on Patients Affected by Breast Cancer in Adjuvant Radiotherapy
NCT04863833Not specifiedUNKNOWNTomosymthesis for Breast Mass Lesion Characterization
NCT05000502Not specifiedCOMPLETEDExercise, Gut Microbiome, and Breast Cancer: Increasing Reach to Underserved Populations
NCT05374161Not specifiedUNKNOWNAn Intervention for Female Breast CANcer: Acceptance and Commitment Therapy (I-CAN-ACT) for Depression and Physical Pain
NCT06331793Not specifiedUNKNOWNPulsed Electromagnetic Fields for Analgesia Post Mastectomy
NCT06332976Not specifiedUNKNOWNPrefeRences And ChemoTherapy In Breast Cancer patiEnts

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
GOSERELIN46
ANASTROZOLE41
ATRACURIUM BESYLATE41
CISATRACURIUM41
FENTANYL CITRATE41
FULVESTRANT41
PALBOCICLIB41
SEVOFLURANE41
CHEMBL540281801
CHEMBL36584701
FLUDEOXYGLUCOSE-F1801

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 20

This page pulls from 20 datasets indexed by BioBTree:

chembl_moleculecivic_evidenceclinical_trialsclinvardoidefogenccgwasgwas_studyhgncmedgenmeshmimmondomondochildmondoparentncitorphanetsctidumls